Breaking AI & Tech News Analyzed

The tragic case of Oliver Robinson, a 34-year-old who took his own life in November 2023, has sparked a campaign for stricter controls on private cannabis clinics in the UK. An inquest concluded that Robinson's prescription for medicinal cannabis, issued by Curaleaf Clinic, probably contributed to his death and acted as an obstacle to him receiving proper psychiatric and addiction care. Robinson had been struggling with depression and addiction, and had been treated at the Priory, a private mental health facility. He was initially prescribed medicinal cannabis in May 2022, which initially provided relief but ultimately worsened his condition. The coroner's report highlighted several failings in his care, including the use of an out-of-date GP summary care record and incomplete information in prescribing decisions. Alexander Robinson, Oliver's brother, is now advocating for tighter regulation of private cannabis clinics, including a ban on prescribing to patients with serious mental illness and greater oversight of the rapidly expanding industry. He believes that the current safeguards are not strong enough to protect vulnerable psychiatric patients. The UK government reported about 5,000 NHS prescriptions for licensed cannabis-based medicinal products in 2023, while freedom of information data showed that 659,293 unlicensed cannabis products were privately prescribed in 2024, more than double the number issued in 2023. Critics argue that there is limited evidence that cannabis is an effective treatment for depression and other common mental health conditions. Dr. Pavan Chahl, an expert psychiatrist, told Oliver's inquest that medicinal cannabis should not have been prescribed to someone with a history of severe psychiatric disorder, citing a lack of evidence for efficacy in depression and the risk of worsening symptoms. In response to the campaign, Curaleaf Clinic stated that it would engage constructively with any review or consultation aimed at strengthening patient safety across the sector.

In Mexico, a mother's determination to navigate the country's beleaguered cancer care system has become a defining feature of her daily life. Faced with a healthcare system in crisis, she finds herself unceasingly vigilant in her quest for adequate treatment.The situation in Mexico's healthcare sector is marked by significant challenges, particularly in the realm of cancer care. Patients and families are often left to struggle with accessing timely and effective treatment, leading to a heavy emotional and financial toll.For this mother, the reality of her child's health battle is a harsh reminder of the system's shortcomings. Her story serves as a poignant example of the human cost of healthcare deficiencies and the resilience of those affected.

Eli Lilly, the US pharmaceutical group behind the Mounjaro weight-loss drug, is seeking to resume its investments in the UK after pausing them last year. The company is in talks with UK ministers to regularly increase NHS drug prices and end a rebate scheme. Patrik Jonsson, president of Eli Lilly's international business, expressed optimism about reaching an agreement this summer.The talks will also explore 'innovative' pricing plans, such as linking payments for anti-obesity drugs to whether the treatment helps patients return to work. This comes as the US pharmaceutical industry increases pressure on the UK, with Keir Starmer agreeing to the first increase in NHS cost-effectiveness thresholds in 27 years. The threshold was raised from £20,000 to £30,000 a year for every year of life gained to £25,000 to £35,000.Eli Lilly was one of several pharmaceutical companies that ditched or paused almost £25bn in planned investments in the UK last year. The company paused its plans to invest in a laboratory site in central London. Jonsson stated that the resumption of Eli Lilly's investment would depend on the outcome of its talks with the government.He emphasized that prices for medicines in the UK had been 'far too low for far too long' and that the threshold couldn't remain static for another three decades. The UK agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal, which could eventually reach £9bn a year.Large pharmaceutical companies have protested about a 'rebate' scheme, under which they are required to pay back a chunk of revenue from sales of branded medicines. This scheme is expected to fall in 2026, although Jonsson believes payments 'should actually get down to zero' over time.

Australian GPs are increasingly turning to AI scribes to record patient notes, with 40% now using the technology, according to a Royal Australian College of GPs (RACGP) online poll. This represents a significant increase from 22% in August 2024.AI tools, such as those offered by Australian company Heidi, record, transcribe, and summarize conversations between doctors and patients for medical notes. Dr. Max Mollenkopf, a GP based in Newcastle, emphasizes the importance of transparency with patients, stating, “We make a big effort to let patients know we are using AI, and give them the option to opt out.”While AI scribes can help relieve doctors' administrative burden, experts point to concerns about consent, privacy, and accuracy. Dr. Elizabeth Deveny, chief executive of the Consumer Health Forum, notes that not all practices are having explicit conversations about the tools with patients.Some GPs see AI scribes as a way to better connect with patients during consultations, allowing them to focus on the patient directly rather than typing notes. However, Dr. Caitlin Curtis, a University of Queensland researcher, warns that outsourcing note-keeping to AI may lead to doctors failing to retain and recall patient conversations.The RACGP president, Dr. Michael Wright, is optimistic about AI tools helping patients and GPs work more closely together, but emphasizes the need for patient consent and verification of AI output. Heidi co-founder Dr. Tom Kelly assures that data is processed securely and not used to train the AI or sold to others.

The UK is on the brink of a medicine shortage crisis, with experts warning that the country is just weeks away from feeling the effects of the ongoing conflict in Iran. The war has already disrupted the supply of essential raw materials, including oil, gas, crop fertiliser, and helium.The pharmaceutical industry, which relies heavily on imports, is particularly vulnerable to these disruptions. India, known as the 'pharmacy of the world', produces a significant proportion of generic drugs and active pharmaceutical ingredients (APIs) used globally. However, with the Strait of Hormuz largely closed due to the conflict, the transportation of these vital supplies is becoming increasingly difficult.Medicine prices are also expected to rise as a result of the conflict. The US-Israel war on Iran has doubled air freight costs, which could make some medicines loss-making to supply to the NHS. While suppliers have long-term pricing agreements with NHS hospitals, they have more flexibility to increase prices for drugs supplied to GP practices and pharmacies.The UK's reliance on imported medicines is significant, with about half of its medicines produced domestically, a third coming from India, and another chunk from the EU. During the Covid pandemic, paracetamol and other painkillers were in short supply in Britain and elsewhere, as drugmakers in India struggled to keep up with demand.Medical distributors typically stock six to eight weeks of supplies to avoid shortfalls, but if the conflict drags on, drug shortages could emerge in only a few weeks' time. Experts warn that the overall ripple effect on the industry is significant, with the patient ultimately picking up the tab, either directly or via public health systems like the NHS.

New York City's public hospital system has announced that it will not be renewing its contract with Palantir, a data analytics and AI firm, amid growing controversy over its government contracts in the UK. The decision comes as health officials in the UK express concerns over data privacy issues related to Palantir's £330m agreement with the National Health Service (NHS).The contract between NYC Health + Hospitals and Palantir, which focused on recovering money for insurance claims, was set to expire in October. According to documents shared with the Guardian, Palantir has paid nearly $4m to the hospital system since November 2023. The contract allowed Palantir to review patient health notes and help the hospital claim more money in public benefits through programs like Medicaid.Despite assurances from NYC Health + Hospitals that there was an 'absolute firewall' preventing Palantir from sharing information with US Immigration and Customs Enforcement (ICE), activists and data privacy experts have raised concerns over the potential risks of Palantir accessing de-identified patient data for purposes other than research.As New York City prepares to part ways with Palantir, the company is expanding its influence in the UK, despite backlash from activists and lawmakers. Palantir has contracts with the British government's Ministry of Defence and is seeking access to sensitive national financial regulation data through a contract with the Financial Conduct Authority.Medact, a health justice charity, has raised concerns that Palantir's software could enable 'data-driven state abuses of power', including US-style ICE raids. In response, Palantir has denied that its data could be used in this way, citing that it would be illegal and a breach of contract.The decision by NYC Health + Hospitals to drop Palantir has been hailed as a victory by activists, who are now calling on the NHS to follow suit and terminate its £330m contract with the company. The 'Purge Palantir' campaign, which involves nurses, pro-Palestinian activists, and social and climate justice groups, aims to stop Palantir from contracting with government agencies, universities, and corporations.

The World Health Organization (WHO) has issued a dire warning about a health crisis unfolding in real time across the Middle East, emphasizing the urgent need for a complete cessation of hostilities to mitigate the humanitarian catastrophe.Dr. Hanan Balkhy, the WHO's regional director for the Eastern Mediterranean, stressed that hospitals and healthcare facilities must be treated as safe havens to protect patients and healthcare workers. The region, encompassing 22 countries and territories including Iran, Gulf states, Gaza, Sudan, Afghanistan, and Pakistan, is facing severe disruptions in healthcare services due to the ongoing conflicts.The violence has resulted in significant loss of life and displacement, with over 1,000 people killed in Lebanon, 1,500 in Iran, and 16 in Israel, alongside reports of numerous deaths in the West Bank and Gulf Arab states. Moreover, 3.2 million people have been displaced in Iran and over 1 million in Lebanon within a month, exacerbating the crisis.Balkhy expressed deep concern about the long-term impacts on maternal mortality, mental health, and the plight of orphaned children left without education. The WHO has verified dozens of attacks on healthcare facilities in Lebanon, Iran, and Israel since the conflict began, including a recent attack on a hospital in Sudan that killed at least 70 people.The organization is also preparing for potential attacks on nuclear sites and water desalination plants, which could have catastrophic health repercussions. Balkhy urged for a significant de-escalation or a permanent pause in hostilities to prevent further humanitarian disaster.

The wait is over for fans of medical dramas, as The Pitt has landed on HBO Max. This 15-episode series, which follows the lives of medical staff in a Pittsburgh hospital, has been generating significant buzz since its release in the US last year.Produced by the same team behind the groundbreaking series ER, The Pitt stars Noah Wyle, known for his iconic role as Dr. John Carter in ER. Wyle plays Dr. Michael 'Robby' Robinavitch, a senior attending physician struggling with PTSD after the loss of his mentor during the pandemic.Each episode covers a single shift in the hospital, delving into the challenges faced by the medical staff as they navigate urgent and complex cases, from gunshot wounds to patients with dementia. The show's pace is more measured than ER, with a focus on character development and nuanced storytelling.The cast is strong, with well-developed characters and backstories that add depth to the narrative. Showrunner John Wells handles the large ensemble with skill, and Wyle is a rock-solid presence at the center of the show.The Pitt explores themes that are both timely and timeless, including the US healthcare system's flaws and the personal and professional struggles of medical staff. With its gripping storylines and strong performances, this series is sure to captivate audiences and leave them eager for more.

The UK government's recent announcement to make significant cuts to direct aid to Africa and the Middle East has been met with deep disappointment. This move is seen as a moral dereliction of duty, betraying the world's most marginalised, and a false economy that will bring greater instability to the world and make people less safe. The cut in aid to 0.3% of gross national income (GNI) from 2027 breaks Labour's 2024 manifesto pledge to restore development spending at the level of 0.7% of GNI “as soon as fiscal circumstances allow”. The UK is making the steepest proportion of aid cuts among G7 nations. As James Mattis, Donald Trump's defence secretary, once said: “If you don’t fund the state department fully, then I need to buy more ammunition ultimately.” This highlights the shortsightedness of cutting aid, which could lead to more conflict, famine, and persecution. The UK itself benefits materially from these investments. The recent inquiry by the all-party parliamentary group on global health and security on international health worker recruitment highlights the extent to which the NHS and wider economy rely on the skills, expertise, and partnerships rooted in the global south. The UK has saved £14bn in training costs through international recruitment and continues to depend on globally trained health professionals. Investment in global vaccination, disease surveillance, and research helps stop outbreaks before they spread internationally and place pressure on health systems. Preventing disease at source is one of the smartest investments we can make to protect patients in Britain. The situation in Somalia, on the edge of famine, underscores the importance of sustained investment in global development. Two consecutive failed rainy seasons have left 6.5 million people in crisis, more than double the number a year ago. The UK's humanitarian relief in Somalia is welcome, but the scrapping of nature funding and cuts to climate aid risk compromising its own strategy of preventing crisis before it takes hold.